134978-97-5

Basic information

• Product Name: 2-(2-(2-Aminoethoxy)ethoxy)acetic acid
• Synonyms: 2-(2-(2-Aminoethoxy)ethoxy)acetic acid;H-AEEAc-OH.HCl;Amino-PEG2-CH2CO2H;Acetic acid,2-[2-(2-aminoethoxy)ethoxy]-;H2N-PEG2-CH2COOH;Amino-PEG2-acetic acid;[2-(2-Aminoethoxy)ethoxy]acetic acid;8-Amino-3,6-dioxaoctanoic acid≥ 99% (HPLC)
• CAS NO: 134978-97-5
• Molecular Formula: C₆H₁₃NO₄
• Molecular Weight: 163.172
• Mol File: 134978-97-5.mol
• Article Data: 12

Chemical Properties

• Melting Point: 124.0 to 128.0 °C
• Boiling Point: 323.8 °C at 760 mmHg
• Flash Point: 149.6 °C
• Appearance: /
• Density: 1.177
• Vapor Pressure: 5.23E-05mmHg at 25°C
• Refractive Index: 1.466
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 3.37±0.10(Predicted)
• CAS DataBase Reference: 2-(2-(2-Aminoethoxy)ethoxy)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-(2-Aminoethoxy)ethoxy)acetic acid(134978-97-5)
• EPA Substance Registry System: 2-(2-(2-Aminoethoxy)ethoxy)acetic acid(134978-97-5)

Safety Data

• Hazardous Substances Data: 134978-97-5(Hazardous Substances Data)

Usage

Description

2-(2-(2-Aminoethoxy)ethoxy)acetic acid, also known as Amino-PEG2-CH2CO2H, is a PEG (polyethylene glycol) compound that features an amino group with a terminal carboxylic acid. This molecule is characterized by its reactivity, as the amine group can interact with carboxylic acids, activated NHS esters, and carbonyls, while the terminal carboxylic acid can form a stable amide bond with primary amine groups in the presence of activators such as EDC or HATU. It is a white to off-white crystalline powder and is utilized in various applications across different industries due to its unique chemical properties.

Uses

Used in Chemically Modified Peptide Nucleic Acid (PNA) Development:
2-(2-(2-Aminoethoxy)ethoxy)acetic acid is used as a probe in the development of chemically modified peptide nucleic acid (PNA) for the qualitative and quantitative detection of DNA. Its unique reactivity allows for the creation of PNA probes that can specifically target and detect DNA sequences, which is crucial in molecular biology and diagnostics.
Used in CovX-bodies Preparation and Studies:
In the pharmaceutical industry, 2-(2-(2-Aminoethoxy)ethoxy)acetic acid is utilized in the preparation and studies of the biological activities of kappa agonist CovX-bodies. These CovX-bodies are engineered protein constructs that can modulate the activity of specific biological targets, such as the kappa opioid receptor, and have potential therapeutic applications in pain management and other conditions.

InChI:InChI=1/C6H13NO4/c7-1-2-10-3-4-11-5-6(8)9/h1-5,7H2,(H,8,9)

Upstream product

• 166108-70-9 [2-(2-dibenzylaminoethoxy)ethoxy]acetic acid 
• 166108-71-0 8-(9-fluorenylmethyloxycarbonyl-amino)-3,6-dioxaoctanoic acid 
• 882518-90-3 N-(2-(2-(2-azidoethoxy)ethoxy))acetic acid 
• 108466-89-3 N-(tert-butyloxycarbonyl)-8-amino-3,6-dioxaoctanoic acid 
• 75001-09-1 2-(2-(2-(1,3-dioxoisoindolin-2-yl)ethoxy)ethoxy)acetic acid 
• 112-27-6 2,2'-[1,2-ethanediylbis(oxy)]bisethanol 
• 77544-68-4 8-tosyloxy-3,6-dioxaoctanol 
• 86520-52-7 2-[2-(2-azidoethoxy)ethoxy]ethanol 

Downstream Products

• 166108-71-0 8-(9-fluorenylmethyloxycarbonyl-amino)-3,6-dioxaoctanoic acid 
• 720695-95-4 [2-(2-{4-[3-(2H-tetrazol-5-yl)-carbazol-9-ylmethyl]benzoylamino}ethoxy)ethoxy]acetic acid 
• 108466-89-3 N-(tert-butyloxycarbonyl)-8-amino-3,6-dioxaoctanoic acid 

Relevant articles and documents

TARGETED BIFUNCTIONAL DEGRADERS

The present invention provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present invention provides bifunctional compounds that can be used to promote or enhance degradation of certain autoantibodies. In certain embodiments, treatment or management of a disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein or the autoantibody in the subject. Thus, in certain embodiments, administration of a compound of the invention to the subject removes or reduces the circulation concentration of the circulating protein or the autoantibody, thus treating, ameliorating, or preventing the disease and/or disorder. In certain embodiments, the circulating protein is TNF.

Preparation method of [2-[1-(Fmoc-amino)ethoxy]ethoxy]acetic acid

The invention provides a preparation method of [2-[1-(Fmoc-amino)ethoxy]ethoxy]acetic acid. The preparation method comprises steps as follows: amino protection is performed on diglycolamine by use ofphthalic anhydride, an obtained intermediate and halo-acetic acid or halo-acetate are subjected to a reaction, deprotection or deprotection and hydrolysis are performed, a product reacts with a Fmoc-based amino protection reagent, and [2-[1-(Fmoc-amino)ethoxy]ethoxy]acetic acid is obtained. In the preparation method, phthalic anhydride and diglycolamine are taken as initial raw materials, short time is required by an amino protection reaction, an obtained intermediate compound has good stability, can be preserved for a long time and does not react with water, water-soluble impurities (such asthe raw material diglycolamine, a byproduct phthalic acid and the like) can be separated through extraction, so that an amino protection product with high purity is obtained, and the purity and the yield of the target product are also improved.

Cell-targeted platinum nanoparticles and nanoparticle clusters

Herein, we report the facile preparation of cell-targeted platinum nanoparticles (PtNPs), through the design of peptides that, as a single molecule added in small concentration during the synthesis, control the size of PtNP clusters during their growth, stabilise the PtNPs in aqueous suspension and enable the functionalisation of the PtNPs with a versatile range of cell-targeting ligands. Water-soluble PtNPs targeted respectively at blood group antigens and at integrin receptors are demonstrated.